CoreWeave Slips Into Oversold Territory on Earnings Plunge. Should You Buy the Dip in CRWV Stock?

CoreWeave (CRWV) shares took a significant hit on Tuesday, dropping by approximately 15% following the release of their Q3 earnings report. While the Livingston-based artificial intelligence (AI) infrastructure company demonstrated strength in the third quarter, their guidance for the future fell short of analysts’ expectations.

Despite a solid performance in Q3, CoreWeave projected revenue of up to $5.15 billion for the full year of 2025, which was lower than the $5.29 billion forecasted by analysts. This disappointing outlook contributed to a 50% decrease in CoreWeave’s stock price from its year-to-date high. The stock’s 14-day Relative Strength Index (RSI) fell below 30, indicating that it may be oversold following the post-earnings selloff.

In addition to the weak guidance, CoreWeave faces structural concerns that suggest reducing exposure to the stock at its current levels. The company carries a substantial debt burden, with net interest expenses exceeding $300 million in Q3. Despite this, CoreWeave plans to increase its spending significantly in the coming year, raising concerns about its financial health.

While CoreWeave’s growing backlog of nearly $56 billion signals strength, the company’s guidance for capital expenditures is a cause for concern, especially considering its ongoing losses. Investors typically value profitability and cost discipline, areas where CoreWeave appears to be lacking at its current price of around $91.

Some investors may point to CoreWeave’s price-sales (P/S) multiple of less than 15x as a reason to remain optimistic about the stock, particularly when compared to competitors like Nvidia with a P/S multiple of around 35x. However, the significant decline in CoreWeave’s stock price in the second half of 2025 has not made it a compelling value proposition, as evidenced by insider selling activity.

According to Barchart data, insider transactions show a lack of buying activity and a significant number of sell orders involving CoreWeave in the past six months. Additionally, CoreWeave’s failure to acquire Core Scientific (CORZ) further undermines its bullish case for the future.

Despite these concerns, Wall Street analysts continue to recommend holding CoreWeave stock for the long term. However, investors should carefully consider the company’s financial health and growth prospects before making any investment decisions.